Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, Mancini GB, Ballantyne CM, Catapano A, Gouni-Berthold I, Stein EA, Xue A, Wasserman SM, Scott R, Thompson PD; GAUSS-3 Investigators. Nissen SE, et al. Clin Cardiol. 2016 Mar;39(3):137-44. doi: 10.1002/clc.22518. Epub 2016 Mar 4. Clin Cardiol. 2016. PMID: 26946077 Free PMC article. Clinical Trial.
Surrogate markers for atherosclerotic disease.
Sankatsing RR, de Groot E, Jukema JW, de Feyter PJ, Pennell DJ, Schoenhagen P, Nissen SE, Stroes ES, Kastelein JJ. Sankatsing RR, et al. Among authors: nissen se. Curr Opin Lipidol. 2005 Aug;16(4):434-41. doi: 10.1097/01.mol.0000174400.68938.f6. Curr Opin Lipidol. 2005. PMID: 15990593 Review.
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Nissen SE, et al. JAMA. 2006 Apr 5;295(13):1556-65. doi: 10.1001/jama.295.13.jpc60002. Epub 2006 Mar 13. JAMA. 2006. PMID: 16533939 Clinical Trial.
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Hazen SL, Ntanios F, Wun CC, Nissen SE. Nicholls SJ, et al. Among authors: nissen se. Am J Cardiol. 2006 Jun 1;97(11):1553-7. doi: 10.1016/j.amjcard.2005.12.042. Epub 2006 Apr 6. Am J Cardiol. 2006. PMID: 16728212 Clinical Trial.
The editor's roundtable: atherosclerosis regression.
Friedewald VE, Ballantyne CM, Nissen SE, Shah PK, Roberts WC. Friedewald VE, et al. Among authors: nissen se. Am J Cardiol. 2008 Apr 1;101(7):967-74. doi: 10.1016/j.amjcard.2007.11.031. Am J Cardiol. 2008. PMID: 18359316 No abstract available.
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden.
Ballantyne CM, Raichlen JS, Nicholls SJ, Erbel R, Tardif JC, Brener SJ, Cain VA, Nissen SE; ASTEROID Investigators. Ballantyne CM, et al. Among authors: nissen se. Circulation. 2008 May 13;117(19):2458-66. doi: 10.1161/CIRCULATIONAHA.108.773747. Epub 2008 Mar 31. Circulation. 2008. PMID: 18378607 Clinical Trial.
554 results